C10
Arzneimittelforschung
1992 Jul;42(7):964-8
Pharmacokinetics of silybin in bile following
administration of silipide (Siliphos®) and silymarin in
cholecystectomy patients.
Schandalik R, Gatti G, Perucca E
Surgical Department, Regional Hospital, Braunau am Inn, Austria.
See
National Library of Medicine Citation
These data indicate that the bioavailability of silybin is much
greater after administration of silipide (Siliphos®) than after
administration of silymarin. This results in increased delivery
of the compound to the liver, which represents the target organ
for pharmacological action.
The biliary excretion of silybin, the main active component of
silymarin, was evaluated by using a specific HPLC method in 9 cholecystectomy
patients with T-tube drainage after intake of oral doses of silipide
(Siliphos®) (Siliphos®) and of silymarin (120mg expressed
as silybin equivalents)
After intake of silipide (Siliphos®), the concentration of
silybin in bile reached a peak within 4 h and declined thereafter
with a mean time of about 10 h. After administration of silymarin,
biliary silybin concentrations were several-fold lower than those
observed after intake of silipide (Siliphos®).
The bile collected after silymarin intake also contained considerable
amounts of isosilybin (a silybin isomer) and very low levels of
silydianin and silycristin. The amount of silybin recovered in
bile in free and conjugated form within 48 h accounted for 11%
of the dose after silipide (Siliphos®) and for 3% of the dose
after silymarin. Plasma silybin concentrations, determined in 3
subjects, were several-fold lower than those in bile after intake
of silipide (Siliphos®) and mostly undetectable after intake
of silymarin.
|